Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020-2022): A retrospective longitudinal SARS-CoV-2 serological surveillance.

Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020-2022): A retrospective longitudinal SARS-CoV-2 serological surveillance.

Publication date: Aug 01, 2023

SARS-CoV-2 anti-spike IgG production and protection from severe respiratory illness should be explored in greater depth after COVID-19 booster vaccination. This longitudinal observational retrospective study investigated the anti-spike IgG response elicited by the first, second and booster doses of BNT162b2 mRNA vaccine in healthcare workers (HCW) at San Martino IRCCS Policlinico Hospital (Genoa) up to the 12 month. Sequential blood sampling was performed at T0 (prior to vaccination), T1 (21 days after the 1 dose of vaccine), T2, T3, T4, T5, T6 (7 days and 1, 3, 6 and 9 months after the 2 dose, respectively), T7 and T8 (1 and 3 months after a booster dose). A SARS-CoV-2 IgG panel (Bio-Rad, Marnes-la-Coquette, France) was used to determine levels of receptor-binding domain (RBD), spike-1 (S1), spike-2 and nucleocapsid structural proteins of SARS-CoV-2. In the 51 HCWs evaluated, seroprevalence was 96% (49/51) at T1 and 100% (51/51) from T2 to T5 for RBD and S1. At T6, only one HCW was negative. T2 [RBD = 2945 (IQR:1693-5364); S1 = 1574 (IQR:833-3256) U/mL], and T7 [RBD = 8204 (IQR:4129-11,912); S1 = 4124 (IQR:2124-6326) U/mL] were characterized by the highest antibody values. Significant humoral increases in RBD and S1 were documented at T7 and T8 compared to T2 and T4, respectively (p-value < .001). Following vaccination with BNT162b2 and a booster dose in the 9 month, nacEFve and healthy subjects show high antibody titers up to 12 months and a protective humoral response against COVID-19 disease lasting up to 20 months after the last booster.

Open Access PDF

Concepts Keywords
Healthcare anti-spike IgG seroprevalence
Mrna Antibodies, Viral
Surveillance Antibodies, Viral
BNT162 Vaccine
BNT162 Vaccine
BNT162b2 vaccine
Follow-Up Studies
Health Personnel
healthcare workers
Immunoglobulin G
Immunoglobulin G
mRNA Vaccine
Retrospective Studies
Seroepidemiologic Studies


Type Source Name
disease VO vaccine
disease IDO production
disease MESH COVID-19
disease VO vaccination
disease IDO blood
disease VO dose
drug DRUGBANK Coenzyme M
disease IDO history
disease VO Comirnaty
disease VO population
disease VO vaccinated
pathway REACTOME Translation
disease VO effective
disease IDO cell
disease MESH infection
disease VO passive immunization
disease MESH chronic renal diseases
disease MESH musculoskeletal diseases
disease MESH HIV infection
disease VO protocol
disease VO time
drug DRUGBANK Etoperidone
drug DRUGBANK L-Valine
disease IDO assay
disease IDO symptom
disease VO USA

Original Article

(Visited 1 times, 1 visits today)